tazobactam has been researched along with fr 264205 in 175 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (fr 264205) | Trials (fr 264205) | Recent Studies (post-2010) (fr 264205) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 202 | 17 | 184 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 62 (35.43) | 24.3611 |
| 2020's | 113 (64.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bulik, CC; Christensen, H; Nicolau, DP | 1 |
| Ge, Y; Livermore, DM; Mushtaq, S | 1 |
| Farrell, DJ; Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Ge, Y; Giske, CG; Karlsson, IM; Titelman, E | 1 |
| Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
| Adam, H; Baxter, M; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, JN; Vanscoy, B | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Adam, H; Chung, P; Denisuik, A; Gin, AS; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Lynch, JP; Rubinstein, E; Schweizer, F; Walkty, A; Zelenitsky, S; Zhanel, GG | 1 |
| Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Chandorkar, G; Hershberger, E; Krishna, G; Miller, B; Wooley, M | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 1 |
| Ambrose, PG; Bhavnani, SM; Castanheira, M; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Steenbergen, JN; VanScoy, BD | 1 |
| Aguilar, L; Gilsanz, F; Gimenez, MJ; Maseda, E | 1 |
| Chandorkar, G; Hershberger, E; Krishna, G; Mouksassi, MS; Xiao, A | 1 |
| Eckmann, C; Solomkin, J | 1 |
| Bassetti, M; Righi, E | 1 |
| Lagarde, C; Mavridou, E; Melchers, MJ; Mouton, JW; Seyedmousavi, S; van Mil, AC | 1 |
| Melchers, MJ; Mouton, JW; van Mil, AC | 1 |
| Nicolau, DP; Sutherland, CA | 2 |
| Huntington, JA; Miller, BW; Nicolau, DP; Xiao, AJ | 1 |
| Burnham, CA; Dubberke, ER; Gonzalez, MD; Hink, T; Wallace, MA | 1 |
| Bowker, KE; MacGowan, AP; Nicholls, D; Noel, AR; Tomaselli, SG | 1 |
| Cluck, D; Lewis, P; Moorman, J; Spivey, J; Stayer, B | 1 |
| Hsu, AJ; Tamma, PD; Tamma, SM | 1 |
| Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P | 1 |
| Scott, LJ | 1 |
| Alkrouk, A; Buehrle, DJ; Chen, L; Clancy, CJ; Hao, B; Kreiswirth, BN; Nguyen, MH; Potoski, BA; Press, EG; Shields, RK | 1 |
| Arya, A; Barber, KE; Hallesy, J; Rybak, MJ; Singh, NB; Smith, JR; Yim, J | 1 |
| Alverdy, J; Hershberger, E; Miller, B; Popejoy, MW; Steenbergen, JN | 1 |
| Aitken, SL; Bhatti, MM; DePombo, AM; Gettys, SC; Kontoyiannis, DP; Nicolau, DP; Nunez, CA; Tverdek, FP | 1 |
| Algora-Weber, A; de la Calle-Pedrosa, N; Delgado-Iribarren, A; Gabán-Díez, Á; González-Jiménez, AI; Hernández-Tejedor, A; Martín-Vivas, A; Merino-Vega, CD; Ruiz de Luna-González, R; Temprano-Gómez, I | 1 |
| Goldstein, EJ; Kullar, R; Long, J; Popejoy, MW; Wagenlehner, FM; Yu, B | 1 |
| Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G | 1 |
| Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR | 1 |
| Abbo, LM; Adachi, J; Aitken, SL; Araos, R; Arias, CA; Bonomo, RA; Jain, R; Lichtenberger, PN; Miller, WR; Munita, JM; Nigo, M; Perez, F; Rakita, R; Rosa, R; Shelburne, S; Shimose, LA; Tran, TT; Wanger, A | 1 |
| Huntington, JA; Long, J; Popejoy, MW | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 2 |
| Davido, B; de Truchis, P; Dinh, A; Salomon, J; Senard, O | 1 |
| Alatoom, A | 1 |
| Cheng, S; Clancy, CJ; Cooper, VS; Doi, Y; Haidar, G; Hao, B; Nguyen, MH; Philips, NJ; Potoski, BA; Press, EG; Shields, RK; Snyder, D | 1 |
| Allworth, AM; Legg, A; McCarthy, KL; Roberts, JA; Stewart, A; Wallis, SC | 1 |
| Chan, E; Hui, SW; Lau, SKP; Martelli, P; Teng, JLL; Woo, PCY | 1 |
| Aguilar-Aguilar, G; Alós-Almiñana, M; Belda-Nacher, JF; Carbonell, JA; Ezquer-Garin, C; Ferriols-Lisart, R | 1 |
| Finklea, JD; Hollaway, R; Jain, R; Le, J; Lee, F; Lowe, K | 1 |
| De Wachter, E; Echahidi, F; Herpol, M; Peeters, C; Piérard, D; Van Dalem, A; Vandamme, P; Wybo, I | 1 |
| Asensio, J; Ayestarán, I; Colomar, A; Delgado, O; Díaz-Cañestro, M; Fraile-Ribot, PA; López-Causapé, C; Maciá, M; Martin-Pena, ML; Mulet, X; Murillas, J; Novo, A; Nuñez, B; Oliver, A; Pérez, JL; Periañez, L; Riera, M; Torres, V | 1 |
| Dorn, C; Kees, F; Kratzer, A; Matzneller, P; Schießer, S; Schlossmann, J; Wulkersdorfer, B; Zeitlinger, M | 1 |
| Cheng, V; Dyer, J; Ingram, P; McWhinney, BC; Raby, E; Rawlins, M; Regli, A; Roberts, JA; Ungerer, JPJ | 1 |
| Dubois, V; Jayol, A; Kieffer, N; Nordmann, P; Ortiz De La Rosa, JM; Poirel, L | 1 |
| Basak, GW; Saran, O; Sulik-Tyszka, B; Wróblewska, MM | 1 |
| Humphries, RM; Spafford, K | 1 |
| Bonomo, RA; Evans, SR | 1 |
| Bradley, JS; Caro, L; Larson, KB; Patel, YT; Rhee, EG; Rizk, ML; Willavize, S | 1 |
| Baklouti, S; Concordet, D; Gandia, P; Guet-Revillet, H; Mane, C; Massip, C; Murris, M | 1 |
| Bonomo, RA; Davis, SL; Dhar, S; File, TM; Gerlach, AT; Kaye, KS; Olson, S; Patel, TS; Perez, F; Pogue, JM; Puzniak, LA; Veve, MP | 1 |
| Kalil, AC; Zavascki, AP | 1 |
| Martín-Asenjo, M; Martín-Guerra, JM | 1 |
| Chen, YH; Cheng, IL; Lai, CC; Tang, HJ | 1 |
| Dorn, C; Eberl, S; Nussbaumer-Pröll, AK; Reiter, B; Stimpfl, T; Zeitlinger, M | 1 |
| Barreto Gutierrez, L; De Bels, D; Gallerani, A; Honore, PM; Kaefer, K; Mugisha, A; Redant, S | 1 |
| Aso, S; Fushimi, K; Goto, H; Kaita, Y; Kojiro, M; Matsui, H; Nakajima, M; Yamaguchi, Y; Yasunaga, H | 1 |
| Freyre-Carrillo, C; García-Martín, S; Martínez Rubio, C; Prado-Montoro, CD; Rodríguez-Iglesias, MA; Ruiz-Aragón, J | 1 |
| Bruno, CJ; Kollef, MH; Réa-Neto, Á; Rhee, EG; Wunderink, RG | 1 |
| Lai, CC; Tang, HJ | 1 |
| Bonomo, RA; Kaye, KS; Perez, F; Pogue, JM | 1 |
| Bassetti, M; Cattelan, A; Giacobbe, DR; Mussini, C; Vena, A | 1 |
| Aguilar, G; Alós, M; Carbonell, JA; Ezquer, C; Ferriols, R; Martínez-Castro, S; Navarro, D; Pastor, E | 1 |
| Akyüz, S; Güdücüoğlu, H; Parlak, M | 1 |
| Carniel, E; Narvaez, GA; Perez, LRR | 1 |
| Millar, BC; Moore, JE; Moore, RE | 1 |
| Cabot, G; Fernández-Esgueva, M; Fraile-Ribot, PA; Huarte, R; López-Calleja, AI; Mulet, X; Oliver, A; Rezusta, A | 1 |
| Jain, M; Mahmoud, A; Nicolau, DP; Nutley, K; Rhodes, NJ; Scheetz, MH; Shah, A; Sutherland, C | 1 |
| Juhász, E; Katona, K; Kristóf, K; Melegh, S; O'Neall, D; Szabó, J; Tóth, Á; Urbán, E | 1 |
| Amore, D; Anile, M; Bassi, M; Cagnetti, S; Carillo, C; D'Agostino, FG; De Giacomo, T; Diso, D; Mantovani, S; Mottola, E; Pagini, A; Pecoraro, Y; Poggi, C; Pugliese, F; Rendina, EA; Russo, G; Vannucci, J; Venuta, F | 1 |
| Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z | 1 |
| Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP | 1 |
| DePestel, DD; Karlowsky, JA; Lob, SH; Motyl, MR; Raddatz, J; Sahm, DF; Young, K | 1 |
| Al-Hasan, MN | 1 |
| Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H | 1 |
| Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E | 1 |
| Concordet, D; Delmas, C; Gandia, P; Georges, B; Jourdan, G; Mané, C; Marcheix, B; Porterie, J; Ruiz, S; Verwaerde, P | 1 |
| Carvalhaes, CG; Duncan, LR; Flamm, RK; Sader, HS; Shortridge, D | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Lence, E; Martínez-Guitián, M; Oliver, A; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Forland, SC; Guerrero-Wooley, RL; Hino, G; Park, SH; Winans, SA | 1 |
| Avdic, E; Beisken, S; Bergman, Y; Cosgrove, SE; Posch, AE; Sharara, SL; Simner, PJ; Tamma, PD | 1 |
| Edpuganti, V; Hall, RG; Kallem, RR; Putnam, WC; Subramaniyan, I | 1 |
| De Ponti, F; Gatti, M; Giannella, M; Raschi, E; Viale, P | 1 |
| Bacca, E; Bedini, A; Bianco, V; Cuomo, G; Franconi, I; Meschiari, M; Mussini, C; Orlando, G | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Oliver, A; Rodiño-Janeiro, BK; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Alves, V; Bou, G; Cantón, R; Cercenado, E; Chaves, C; Delgado-Valverde, M; Díaz-Regañón, J; Diogo, J; Ferreira, R; García-Castillo, M; García-Fernández, S; Gonçalves, E; Hernández-García, M; López-Mendoza, D; Melo-Cristino, J; Oliver, A; Paixão, L; Pássaro, L; Pinto, MF; Pitart, C; Ramalheira, E; Rodríguez-Lozano, J; Romano, J; Sancho, L; Silva, T; Tormo, N; Vieira, AR | 1 |
| Lipman, J; Pandey, S; Parker, SL; Roberts, JA; Sime, FB; Stuart, J; Wallis, SC | 1 |
| Arcay, RM; Cantón, R; Castillo, FJ; Cercenado, E; Cisterna, R; Díaz-Regañón, J; Gálvez-Benítez, L; González Romo, F; Hernández-Cabezas, A; López-Mendoza, D; Loza, E; Rodríguez-Lozano, J; Suárez-Barrenechea, AI; Tubau, F | 1 |
| Baccani, I; Bartalesi, F; Bartoloni, A; Borchi, B; Bresci, S; Cavallo, A; Ottino, L; Rossolini, GM | 1 |
| Murri, R; Sacco, E | 1 |
| Betthauser, KD; Kollef, MH; Lizza, BD; Micek, ST; Ritchie, DJ | 1 |
| Chatfield, MD; Harris, PNA; Littleford, R; Paterson, DL; Stewart, AG | 1 |
| Bauer, T; Berbescu, S; Bouchand, F; Davido, B; de Laroche, M; Dinh, A; Duran, C; Matt, M; Nich, C; Noussair, L; Pagis, V; Rempenault, C; Rottman, M; Salomon, E | 1 |
| Ariano, R; Bassetti, M; Baxter, M; Borgia, S; Cervera, C; Dhami, R; Dow, G; Dube, M; Irfan, N; Karlowsky, JA; Kosar, J; Savoie, M; Tessier, JF; Walkty, A; Zhanel, GG; Zvonar, R | 1 |
| Jamieson, C; Jenkins, A; Santillo, M; Shanu, S | 1 |
| Akrich, B; Amode, A; Berthelot, A; Boutoille, D; Castan, B; Levy-Bachelot, L; Mackosso, C; Mathis, L; Mootien, J; Ruimy, R; Ruiz, F; Timsit, JF | 1 |
| Al Jalali, V; Dorn, C; Kratzer, A; Lackner, E; Matzneller, P; Österreicher, Z; Taubert, M; Wölfl-Duchek, M; Wulkersdorfer, B; Zeitlinger, M | 1 |
| Cazorla-Poderoso, L; Huarte-Lacunza, R; Larrodé-Leciñena, I; López-Calleja, AI; Magallón-Martínez, A; Martínez-Álvarez, RM; Pereira-Blanco, O; Pérez-Moreno, M; Pinilla-Rello, A | 1 |
| Daragon, B; Fournier, D; Jeannot, K; Plésiat, P | 1 |
| Bremmer, DN; Kline, EG; Nicolau, DP; Shah, S; Shields, RK | 1 |
| DePestel, DD; DeRyke, CA; Garrison, MW; Harris, KA; Moise, PA; Pfaller, MA; Sader, HS; Shortridge, D | 1 |
| Horcajada, JP; López Montesinos, I; Montero, M; Sorlí, L | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Alcalde-Rico, M; Arias, CA; García, P; Khan, A; Martínez, JRW; Miller, WR; Moreno, MV; Munita, JM; Olivares-Pacheco, J; Rivas, L; Rojas, P; Wozniak, A | 1 |
| Chen, WT; DeRyke, CA; Kazmierczak, KM; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Meesing, A; Sribenjalux, W; Wonglakorn, L | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-Pérez, B; Fraile-Ribot, PA; Gato, E; González-Bello, C; Guijarro-Sánchez, P; Gutiérrez-Urbón, JM; Lasarte-Monterrubio, C; Oliver, A; Oviaño, M; Ruedas-López, A; Vallejo, JA; Vázquez-Ucha, JC; Velasco, D | 1 |
| Attou, R; Barreto Gutierrez, L; Boer, W; De Bels, D; Gallerani, A; Honore, PM; Kaefer, K; Moorthamers, S; Preseau, T; Redant, S | 1 |
| Bruno, CJ; Butterton, JR; Gates, D; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Motyl, M; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Bourguignon, L; Dheyriat, L; Ferry, T; Goutelle, S; Perpoint, T | 1 |
| Cabot, G; Gomis-Font, MA; Juan, C; López-Argüello, S; Moyá, B; Oliver, A; Zamorano, L | 1 |
| Al Musawa, M; Alattas, M; Alfahad, W; Alfozan, A; Alghamdi, A; Alhameed, AF; Aljabri, A; Almangour, TA; Almohaizeie, A; Almuhisen, S; Alraddadi, BM; AlShahrani, FS; Binkhamis, KM; Damfu, N; Khuwaja, M; Qutub, M | 1 |
| Al-Alawi, MM; Ali, HE; Almutairi, AF; AlTurki, R; Bahabri, NM; Janah, SS; Khalil, S; Qutub, MO; Tashkandi, WA | 1 |
| Carratalà, J; Cuervo, G; González Laguna, M; Llop Talaveron, J; Padullés, A; Pérez-Recio, S; Ronda, M; Soldevila-Boixader, L; Tubau Quintano, MF | 1 |
| Csékó, AB; Gál, J; Hermann, C; Iványi, ZD; Mogyoródi, B | 1 |
| Chew, KL; Leong, Q | 1 |
| Candel, FJ; González Del Castillo, J; Julián Jiménez, A; Matesanz, M | 1 |
| DeRyke, CA; Hilbert, DW; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Wong, MT; Young, K | 1 |
| Ju, YG; Lee, HJ; Lee, MG; Sohn, JW; Yim, HS; Yoon, YK | 1 |
| Benítez-Cano, A; Grau, S; Luque, S; Navarrete-Rouco, ME; Roberts, JA; Sorlí, L | 1 |
| Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A | 1 |
| Bassetti, M; Bruno, CJ; Castanheira, M; Huntington, JA; Jensen, EH; Johnson, MG; Motyl, M; Paterson, DL; Wolf, DJ; Yu, B | 1 |
| Antonelli, A; Brenciani, A; Brescini, L; Castelletti, S; Cirioni, O; D'Achille, G; Di Pilato, V; Fioriti, S; Giacometti, A; Giani, T; Giovanetti, E; Masucci, A; Mingoia, M; Morroni, G; Rossolini, GM | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Oliver, A; Rumbo-Feal, S; Vázquez-Ucha, JC | 1 |
| Castanheira, M; Collingsworth, TD; DeVries, S; Doyle, TB; Hubler, CM; Mendes, RE | 1 |
| Gillani, SW; Hussain, MW; Mahmood, RK; Rathore, HA; Saeed, MW; Vippadapu, P | 1 |
| Alosaimy, S; Amaya, L; Biagi, M; Chandler, E; Cubillos, A; Davis, SL; Finch, N; Hobbs, ALV; Holger, D; Jorgensen, SCJ; Kufel, WD; Kunz Coyne, AJ; Lagnf, AM; Li, D; Molina, KC; Moore, WJ; Morrisette, T; Mubarez, M; Patch, M; Polisetty, RS; Rebold, N; Rico, M; Rybak, MJ; Sakoulas, G; Simon, SP; Smith, IMK; Tran, NN; Truong, J; Venugopalan, V; Veve, MP; Witucki, P; Wrin, J; Yost, C | 1 |
| Bensaci, M; Bruno, CJ; Chen, G; Chen, X; Du, X; Fan, J; Huntington, JA; Johnson, MG; Sun, F; Sun, Y; Wang, H; Wang, Y | 1 |
| Castanheira, M; Chen, WT; Pfaller, M; Shortridge, D; Streit, J; Tulloch, M | 1 |
| Bruno, CJ; De Anda, C; Feng, HP; Fiedler-Kelly, J; Gao, W; Patel, YT; Rhee, EG; Zhang, Z | 1 |
| Abbara, D; Afaneh, L; Al Duhailib, Z; Al Qahtani, MM; Al Sulaiman, K; Aldhayyan, N; Askar, G; Dyab, N; Hakeam, HA; Islami, M; Mansour, R | 1 |
| Bruno, C; Dillon, RJ; Khankhel, ZS; Puzniak, L; Thosar, M | 1 |
| Anda, C; Bruno, CJ; Feng, HP; Fiedler-Kelly, J; Gao, W; Johnson, MG; Patel, YT; Rhee, EG; Zhang, Z | 1 |
| Alekseeva, I; DeRyke, CA; Estabrook, MA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Maseda, E; Suárez de la Rica, A | 1 |
| Baretta, V; Calore, E; Carraro, F; Cesaro, S; Colombini, A; Meazza, C; Muggeo, P; Onofrillo, D; Perruccio, K; Rosaria D'Amico, M; Zama, D | 1 |
| Gill, CM; Nicolau, DP | 2 |
| Bruno, CJ; Huntington, JA; Jensen, EH; Kollef, MH; Martin-Loeches, I; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Alekseeva, I; DeRyke, CA; Hawser, SP; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH | 1 |
| Böhringer, N; Horst, J; Hübner, J; Kappler, M; Kolberg, L; Kresna, IDM; Liu, Y; Marner, M; Mettal, U; Meyer-Bühn, M; Mihajlovic, S; Schäberle, TF; von Both, U; Wang, L | 1 |
| Carvalho, TN; Deglmann, RC; França, PHC; Hille, D; Kobs, VC; Melo, LH | 1 |
| Amara, M; Barraud, O; Bastide, M; Bernabeu, S; Bille, E; Bonnin, RA; Brun, CL; Cattoir, V; Corvec, S; d'Epenoux, LR; Degand, N; Dortet, L; Emeraud, C; Farfour, E; Fihman, V; Grillon, A; Guillard, T; Isnard, C; Jacquier, H; Janvier, F; Jousset, AB; Laurent, F; Lemonnier, A; Lomont, A; Merens, A; Mizrahi, A; Plouzeau, C; Ranc, AG; Soismier, N; Yin, N; Zahar, JR | 1 |
| Cabot, G; Khajehpour, M; Kim, K; Mark, BL; Oliver, A | 1 |
| Jia, P; Xu, Y; Yang, Q; Yu, W; Zhang, H; Zhu, Y | 1 |
| Ballesta, S; López, CE; López-Cerero, L; Pascual, A; Rojo-Martin, MD; Sánchez-Yebra, W | 1 |
| Arends, SJR; Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Akrich, B; DeRyke, CA; Hawser, SP; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Aja-Macaya, P; Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-González, A; Galán-Sánchez, F; González-Mayo, E; Guijarro-Sánchez, P; Lada-Salvador, P; Lasarte-Monterrubio, C; Martínez-Guitián, M; Muíño-Andrade, M; Oliver, A; Rodríguez-Iglesias, M; Rumbo-Feal, S; Vázquez-Ucha, JC; Vela-Fernández, R | 1 |
| Bogiel, T; Grabowska, M; Sękowska, A | 1 |
| Bensaci, M; Bruno, CJ; De Anda, C; Dementieva, N; Huntington, JA; Jackson, CA; Johnson, MG; Lonchar, J; Newland, J; Popejoy, MW; Rhee, EG; Su, FH | 1 |
| Deng, T; Kong, W; Li, S; Shu, Y; Wu, Y | 1 |
| Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K | 1 |
| Hsueh, PR; Lee, YL | 1 |
| Chen, TY; Hsu, CK; Lai, CC; Shih, SC; Tang, HJ; Weng, TS | 1 |
| Hsueh, PR; Ko, WC; Lee, YL | 1 |
| Fujimori, T; Hagiya, H; Higashikage, A; Iio, K; Kakehi, A; Minabe, H; Okura, M; Otsuka, F; Yokoyama, Y | 1 |
| Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J | 1 |
| Faurholt-Jepsen, D; Jensen, PØ; Johansen, HK; Katzenstein, TL; Kolpen, M; Pressler, T; Qvist, T | 1 |
| Agyeman, AA; Boyce, JD; Bulitta, JB; Cortés-Lara, S; Figuerola, J; Fraile-Ribot, P; Franklyn, ERT; Gomis-Font, MA; Landersdorfer, CB; Lang, Y; Lee, WL; López-Causapé, C; Lucas, DD; Nation, RL; Oliver, A; Rogers, KE; Zhang, Y; Zhou, J | 1 |
| Abbott, IJ; Chang, CC; Dennison, A; Kostoulias, X; Peleg, AY; Spelman, DW; Wisniewski, J; Zisis, H | 1 |
| Al Musawa, M; Alanazi, MQ; Alassiri, D; Alfahad, W; Alghaith, J; Alharbi, A; Aljefri, D; Aljurbua, A; Almangour, TA; Almohaizeie, A; Almuhisen, S; Alsowaida, YS; Damfu, N; Ghonem, L; Khormi, Y | 1 |
| Chen, WT; Cheng, MH; Hsieh, TC; Karlowsky, JA; Lu, HC; Motyl, MR; Sahm, DF; Siddiqui, F; Wise, MG; Young, K | 1 |
| Abidi, E; Al Ali, M; Attallah, N; El Lababidi, R; El Nekidy, WS; Ghazi, IM; Hijazi, F; Mallat, J | 1 |
| Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR | 1 |
| Adam, H; Blondeau, J; Charles, MK; El Ali, R; Ghakis, C; Gonzalez Del Vecchio, M; Loo, V; O'Callaghan, E | 1 |
17 review(s) available for tazobactam and fr 264205
| Article | Year |
|---|---|
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2014 |
Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Enzyme Inhibitors; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2014 |
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2015 |
Ceftolozane-tazobactam: A new-generation cephalosporin.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Penicillanic Acid; Tazobactam | 2015 |
Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Humans; Intraabdominal Infections; Multicenter Studies as Topic; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2016 |
The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials.
Topics: Cephalosporins; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Tazobactam; Urinary Tract Infections | 2020 |
Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review.
Topics: Cephalosporins; Continuous Renal Replacement Therapy; Humans; Obesity; Tazobactam | 2020 |
Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Systematic review of the stability of antimicrobial agents in elastomeric devices for outpatient parenteral antimicrobial therapy services based on NHS Yellow Cover Document standards.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefazolin; Ceftazidime; Floxacillin; Humans; Outpatients; Piperacillin; State Medicine; Tazobactam | 2022 |
Ceftolozane-tazobactam: When, how and why using it?
Topics: Anti-Bacterial Agents; Cephalosporins; Colistin; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Ceftolozane-tazobactam in nosocomial pneumonia.
Topics: Adult; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pseudomonas Infections; Tazobactam | 2022 |
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2022 |
Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR).
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Communicable Diseases; Humans; Tazobactam | 2022 |
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2022 |
Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Network Meta-Analysis; Tazobactam; Tigecycline | 2023 |
Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Tazobactam | 2023 |
16 trial(s) available for tazobactam and fr 264205
| Article | Year |
|---|---|
Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Penicillanic Acid; Renal Insufficiency; Tazobactam; Young Adult | 2015 |
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Pneumonia; Tazobactam; Young Adult | 2016 |
Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Female; Humans; Intraabdominal Infections; Male; Metronidazole; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2016 |
Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Penicillanic Acid; Renal Insufficiency; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Diabetes Mellitus; Female; Humans; Intraabdominal Infections; Levofloxacin; Male; Metronidazole; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2017 |
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Humans; Lung; Pneumonia; Tazobactam | 2020 |
Development and validation of a quantitative LC-MS/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine.
Topics: Cephalosporins; Chromatography, Liquid; Humans; Limit of Detection; Linear Models; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2020 |
Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferior
Topics: Adult; Anti-Bacterial Agents; Australia; beta-Lactamases; Cephalosporins; Clostridioides difficile; Escherichia coli; Humans; Italy; Lebanon; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Saudi Arabia; Sepsis; Singapore; Spain; Tazobactam | 2021 |
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Tazobactam; Ventilators, Mechanical | 2022 |
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Retrospective Studies; Tazobactam; Ventilators, Mechanical | 2022 |
A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; China; Double-Blind Method; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Tazobactam | 2022 |
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Kidney Failure, Chronic; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Probability; Renal Dialysis; Tazobactam; Ventilators, Mechanical | 2023 |
Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Topics: Anti-Bacterial Agents; Bacteria; Cephalosporins; Hospitals; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tazobactam; Ventilators, Mechanical | 2023 |
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Monobactams; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tazobactam; Vasoconstrictor Agents; Ventilators, Mechanical | 2022 |
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Infant, Newborn; Meropenem; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2023 |
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Penicillanic Acid; Tazobactam | 2023 |
142 other study(ies) available for tazobactam and fr 264205
| Article | Year |
|---|---|
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Young Adult | 2010 |
Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2010 |
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.
Topics: Bacteroides fragilis; Cephalosporins; Drug Resistance, Bacterial; Enterobacteriaceae; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2011 |
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia coli Infections; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Typing; Penicillanic Acid; Tazobactam | 2011 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
Topics: Anti-Bacterial Agents; Canada; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2013 |
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Computer Simulation; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Escherichia coli; Escherichia coli Infections; Gene Expression; Half-Life; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Plasmids; Tazobactam | 2013 |
Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteroides fragilis; Cephalosporins; Clostridium; Drug Combinations; Fusobacterium; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Prevotella; Propionibacterium; Tazobactam | 2014 |
Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2014 |
Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.
Topics: Adolescent; Adult; Aged; Cephalosporins; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Penicillanic Acid; Prospective Studies; Tazobactam; Young Adult | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cephalosporins; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Genotype; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.
Topics: Anti-Bacterial Agents; Cephalosporins; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2014 |
Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Enterobacteriaceae; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Investigational New Drug Application; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2015 |
Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Female; Klebsiella pneumoniae; Mice; Penicillanic Acid; Protein Binding; Tazobactam; Thigh | 2015 |
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2015 |
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Topics: Adult; Anti-Infective Agents; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; United States | 2015 |
Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.
Topics: Anti-Bacterial Agents; Cephalosporins; Clostridioides difficile; Microbial Sensitivity Tests; Penicillanic Acid; Phylogeny; Tazobactam | 2015 |
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Bioreactors; Cephalosporins; Chromatography, High Pressure Liquid; Colony Count, Microbial; Computer Simulation; Escherichia coli; Gene Expression; Half-Life; Infusion Pumps; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Porins; Pseudomonas aeruginosa; Tazobactam | 2016 |
Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.
Topics: Anti-Bacterial Agents; Cephalosporins; Child; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2016 |
Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Prospective Studies; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2015 |
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 2016 |
Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Plasma; Reproducibility of Results; Sodium Chloride; Swine; Tazobactam | 2016 |
Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
Topics: Anti-Bacterial Agents; Cefazolin; Cephalosporins; Daptomycin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillanic Acid; Staphylococcus aureus; Tazobactam | 2016 |
Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Child; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Leukemia; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Off-Label Use; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins | 2017 |
Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
Topics: Animals; Anti-Bacterial Agents; Cattle; Cephalosporins; Drug Dosage Calculations; Hemodialysis Solutions; Humans; Membranes, Artificial; Metabolic Clearance Rate; Models, Biological; Penicillanic Acid; Renal Replacement Therapy; Tazobactam | 2017 |
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Female; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2017 |
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; United States | 2017 |
Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam: two effective antimicrobial agents against multidrug-resistant organisms except for NDM-1 isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Penicillanic Acid; Tazobactam | 2017 |
Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam against multidrug-resistant organisms.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Penicillanic Acid; Tazobactam | 2017 |
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Genome, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pennsylvania; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Young Adult | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cephalosporins; Humans; Infusions, Parenteral; Lung Abscess; Male; Microbial Sensitivity Tests; Middle Aged; Outpatients; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Topics: Anti-Bacterial Agents; Burkholderia pseudomallei; Cephalosporins; Microbial Sensitivity Tests; Tazobactam | 2018 |
Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma.
Topics: Anti-Bacterial Agents; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Plasma; Tazobactam | 2018 |
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam | 2018 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Burkholderia cepacia complex; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Humans; Microbial Sensitivity Tests; Sulfamethoxazole; Tazobactam; Trimethoprim | 2018 |
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
Topics: Aged; Cephalosporins; Drug Resistance, Multiple, Bacterial; Factor Analysis, Statistical; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2018 |
Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV.
Topics: Anti-Bacterial Agents; Cephalosporins; Chemical Fractionation; Chromatography, High Pressure Liquid; Extracellular Fluid; Healthy Volunteers; Humans; Infusions, Intravenous; Spectrophotometry, Ultraviolet; Tazobactam | 2019 |
Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cephalosporins; Female; Half-Life; Humans; Kidney Failure, Chronic; Middle Aged; Osteomyelitis; Pseudomonas aeruginosa; Renal Replacement Therapy; Tazobactam | 2018 |
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Hospitals; Humans; Microbial Sensitivity Tests; Patients; Poland; Pseudomonas; Pseudomonas Infections; Tazobactam | 2019 |
Letter to the Editor.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Pathology, Molecular; Pseudomonas aeruginosa; Tazobactam | 2019 |
Reply to Humphrey and Spafford.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Pathology, Molecular; Pseudomonas aeruginosa; Tazobactam | 2019 |
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Tazobactam; Urinary Tract Infections; Young Adult | 2019 |
Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients
Topics: Azabicyclo Compounds; Burkholderia cepacia complex; Burkholderia gladioli; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Humans; Tazobactam | 2019 |
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2020 |
Can ceftolozane-tazobactam treat nosocomial pneumonia?
Topics: Cephalosporins; Cross Infection; Double-Blind Method; Humans; Meropenem; Pneumonia; Tazobactam | 2019 |
Reply to "Hypokalaemia probably associated with ceftolozane/tazobactam treatment: Three case reports".
Topics: Cephalosporins; Humans; Hypokalemia; Tazobactam | 2020 |
Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Urinary Tract Infections | 2020 |
Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights.
Topics: Cephalosporins; Continuous Renal Replacement Therapy; Critical Illness; Humans; Tazobactam | 2019 |
Effect of high-dose vitamin C therapy on severe burn patients: a nationwide cohort study.
Topics: Adult; Ascorbic Acid; Burns; Cephalosporins; Cohort Studies; Continuous Renal Replacement Therapy; Critical Illness; Humans; Tazobactam | 2019 |
[Evaluation of susceptibility of multidrug-resistant Pseudomonas aeruginosa strains against ceftolozane/tazobactam].
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Mass Spectrometry; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Real-Time Polymerase Chain Reaction; Reference Values; Reproducibility of Results; Tazobactam | 2019 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia - Authors' reply.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Reply to Vena et al.
Topics: Aminoglycosides; Cephalosporins; Humans; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Tazobactam | 2020 |
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome | 2020 |
Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances.
Topics: Cephalosporins; Continuous Renal Replacement Therapy; Tazobactam | 2020 |
[In-vitro Activity of Ceftolozane-Tazobactam in Combination with Various Antibiotics Against Multidrug-resistant Acinetobacter baumannii Isolated from Intensive Care Patients].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Tazobactam | 2020 |
High minimum inhibitory concentrations among derepressed AmpC-beta-lactamase-producing
Topics: Bacterial Proteins; beta-Lactamases; Brazil; Cephalosporins; Enterobacter cloacae; Humans; Microbial Sensitivity Tests; Tazobactam | 2020 |
Antimicrobial susceptibility of plastic-associated bacteria isolated from the ocean to novel antibiotics (delafloxacin, meropenem/vaborbactam, ceftolozane/tazobactam, ceftobiprole) - Can environmental bacteria be predictors of persistence of antibiotic ac
Topics: Antarctic Regions; Anti-Bacterial Agents; Bacteria; Boronic Acids; Cephalosporins; Drug Resistance, Microbial; Fluoroquinolones; Islands; Meropenem; Oceans and Seas; Plastics; Polystyrenes; Tazobactam | 2020 |
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Hungary; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Lung Transplantation; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United State
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2021 |
Gram-negative Bacteria With Difficult-to-Treat Resistance: A Moving Target.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Imipenem; Phenotype; Tazobactam | 2021 |
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Greece; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Critical Illness; Extracorporeal Membrane Oxygenation; Humans; Swine; Tazobactam | 2020 |
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Europe; Europe, Eastern; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Meningitis; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tazobactam | 2021 |
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
Topics: Anti-Bacterial Agents; Cephalosporins; Continuous Renal Replacement Therapy; Critical Illness; Humans; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Renal Replacement Therapy; Tazobactam | 2021 |
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2021 |
A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies.
Topics: Anti-Bacterial Agents; Cephalosporins; Chromatography, Liquid; Humans; Pharmaceutical Preparations; Renal Replacement Therapy; Tandem Mass Spectrometry; Tazobactam | 2021 |
Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2021 |
Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Humans; Italy; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam; Young Adult | 2021 |
What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections?
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2021 |
Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study.
Topics: Aged; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cohort Studies; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tazobactam | 2021 |
Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
Topics: Anti-Bacterial Agents; Canada; Cephalosporins; Humans; Leadership; Registries; Tazobactam | 2021 |
Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France.
Topics: Adult; Cephalosporins; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthy Volunteers; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Microdialysis; Penicillanic Acid; Prospective Studies; Pseudomonas aeruginosa; Tazobactam | 2021 |
[Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
Topics: Aftercare; Aged; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Patient Discharge; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2021 |
Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Endocarditis; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2021 |
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam | 2021 |
Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Thailand | 2022 |
In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam.
Topics: Azabicyclo Compounds; Burkholderia pseudomallei; Ceftazidime; Cephalosporins; Humans; Melioidosis; Pseudomonas aeruginosa; Tazobactam; Thailand | 2022 |
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT.
Topics: Cephalosporins; Humans; Meropenem; Tazobactam | 2022 |
Pharmacokinetic/Pharmacodynamic Simulations of Cost-Effective Dosage Regimens of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Patients with Renal Impairment.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cost-Benefit Analysis; Drug Combinations; Humans; Microbial Sensitivity Tests; Tazobactam | 2022 |
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Clone Cells; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Saudi Arabia; Tazobactam | 2022 |
Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Tertiary Care Centers | 2022 |
Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Drug resistance rates of difficult to treat Pseudomonas aeruginosa isolates to ceftolozane-tazobactam and ceftazidime-avibactam from a tertiary hospital, Singapore.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Singapore; Tazobactam; Tertiary Care Centers | 2022 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2022 |
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Combinations; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Rifampin; Tazobactam; Tigecycline | 2022 |
Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Monitoring; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam | 2022 |
Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Cyclooctanes; Humans; Imipenem; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel β-lactam/β-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Gene Expression Profiling; Humans; Lactams; Lipopolysaccharides; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; beta-Lactams; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam; Vancomycin | 2023 |
Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Meropenem; Microbial Sensitivity Tests; New Zealand; Penicillanic Acid; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2022 |
Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.
Topics: Carbapenems; Cefepime; Ceftazidime; Phenotype; Pseudomonas aeruginosa; Tazobactam | 2022 |
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020.
Topics: Anti-Bacterial Agents; Cephalosporins; Czech Republic; Humans; Hungary; Imipenem; Microbial Sensitivity Tests; Poland; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
Topics: Adolescent; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.
Topics: Anti-Bacterial Agents; beta-Lactamases; Brazil; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Hospitals, General; Klebsiella pneumoniae; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2023 |
Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Escherichia coli; Humans; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Biochemical Insights into Imipenem Collateral Susceptibility Driven by
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporinase; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Klebsiella pneumoniae; Pseudomonas aeruginosa; Tazobactam | 2023 |
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam | 2023 |
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Intraabdominal Infections; Metronidazole; Penicillanic Acid; Tazobactam | 2023 |
Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporinase; Cephalosporins; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Topics: Adolescent; Anti-Bacterial Agents; Biofilms; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia.
Topics: Adult; Anti-Bacterial Agents; Australia; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cohort Studies; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2023 |
Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan-SMART 2012-2021.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Enterobacteriaceae; Humans; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Taiwan; Tazobactam | 2023 |
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Continuous Renal Replacement Therapy; Female; Humans; Male; Retrospective Studies; Tazobactam | 2023 |
Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
Topics: Anti-Bacterial Agents; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
A nested cohort 5-year Canadian surveillance of Gram-negative antimicrobial resistance for optimized antimicrobial therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Canada; Drug Resistance, Bacterial; Escherichia coli; Humans; Tazobactam | 2023 |